Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

A marker-standardized Melastoma malabathricum leaf extract-poly(lactic-co-glycolic acid) nanocurcumin hydrogel improves repair in splinted diabetic wounds in mice.

Created on 26 Aug 2026

Authors

Thi Phuong Nhung Tran, Hong Quan Bui, Thi Truc Ly Le, Hoa Hong Chau Truong

Published in

The Journal of pharmacy and pharmacology. Volume 78. Issue 8. Aug 03, 2026.

Abstract

To develop a marker-standardized Melastoma malabathricum leaf extract-poly(lactic-co-glycolic acid) (PLGA) nanocurcumin hydrogel and test whether Chou-Talalay-guided ratio selection improves diabetic wound repair.
The extract was standardized using phenolic and flavonoid indices, high-performance liquid chromatography with diode-array detection fingerprinting, and quantification of gallic acid and quercetin. PLGA nanocurcumin was qualified for particle size, surface charge, encapsulation, and release. Cytocompatibility, migration, inflammatory responses, reactive oxygen species-related redox responses, and fixed-ratio interactions were assessed in keratinocytes, macrophages, and fibroblasts. The Chou-Talalay-selected ratio was incorporated into a Carbopol hydrogel and tested in splinted diabetic excisional wounds in mice.
Both components met predefined quality criteria. The 1:1 equipotent ratio showed consistent synergy and was formulated at 2.0 mg extract plus 0.2 mg curcumin-equivalent PLGA nanocurcumin per 0.1 g gel. The hydrogel showed acceptable quality, release, retention, and 30-day stability. It improved Day 14 wound closure compared with vehicle, from 56 ± 8% to 90 ± 2%, with greater histological repair, collagen maturation, and hydroxyproline content. Supportive tissue markers indicated lower inflammation, improved redox balance, repair-associated macrophage marker shifts, angiogenesis, and matrix remodelling.
This ratio-defined, marker-standardized extract-PLGA nanocurcumin hydrogel improved diabetic wound repair and provides a quality-controlled, quantitatively optimized topical platform for further preclinical development.

PMID:
42641063
Bibliographic data and abstract were imported from PubMed on 26 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 8
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement